AKT1 and breast carcinoma: Several single‐node PAM inhibitors are FDA‐approved for advanced breast cancer in combination with hormonal therapy, including everolimus (mTORC1 inhibitor), alpelisib (PI3Kα inhibitor), and capivasertib (AKT inhibitor).